MCRPF News and Press, Microport Scientific Corp

2023-11-12 06:48:07 ET Summary Stereotaxis was forced to do a human trial for its Magic catheter before it can get CE Mark. This is starting in a few weeks. Stereotaxis will soon submit a PMA for FDA approval of the Magic catheter 180 days after submission. China is set to app...

San Diego-based Kumquat Biosciences announced a $2 billion agreement with a Lilly subsidiary to discover small-molecule drugs that stimulate tumor-specific immune responses in cancer patients. Sirnaomics, a Maryland-Suzhou RNAi therapeutics company, filed to raise $300 million in a Ho...

Elevator Pitch I maintain my "Neutral" rating on Hong Kong-listed medical device manufacturer MicroPort Scientific Corporation ( OTCPK:MCRPF ) [853:HK]. MicroPort Scientific has revised the company's revenue growth guidance for FY2020 downwards as a result of the coronavirus pandemic. Mic...

Elevator Pitch Hong Kong-listed medical device manufacturer MicroPort Scientific Corporation ( MCRPF ) [853:HK] is a long-term play on growing healthcare demand with its dominant coronary stent products and other new products in the pipeline. The stock's 32.7 times consensus forward FY2020 P...

SHANGHAI , Sept. 4, 2018 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort®", HK:0853) announced today that the clinical trial results for its Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") which conducted a multi-center, randomized c...

Firehawk® Clinical Data From The TARGET AC European Clinical Trial Has Been Accepted For Publication In The Prestigious Medical Journal The Lancet Canada NewsWire SHANGHAI, Sept. 3, 2018 SHANGHAI , Sept. 3, 2018 /CNW/ -- MicroPort Scientific Corporation ("MicroP...

The following slide deck was published by Microport Scientific Corp. in conjunction with their 2017 Q4 earnings Read more ...